NasdaqCM - Nasdaq Real Time Price ? USD Traws Pharma, Inc. (TRAW) Follow Compare 5.05 -0.05 (-0.98%) As of 12:40 PM EDT. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil Investigational agent in development as a one dose treatment or prevention of seasonal and pandemic influenza A dose ranging, Phase 1 study in healthy volunteers demonstrated positive tolerability results and plasma levels in the predicted therapeutic window, enabling selection of Phase 2 dose Preclinical data showed potent inhibition of drug-resistant and bird influenza viruses Phase 2 study expected to begin in H1 2025 Improved therapy is an important need for both seasonal and pandemic flu NE GlobeNewswire ? 24 days ago TRAW -0.98% Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor Ratutrelvir was well-tolerated for 10 days and achieved consistent plasma levels in the predicted therapeutic window, without the need for co-administration of ritonavir Phase 2a study expected to begin in H1 2025 in patients with COVID Improving COVID care is an ongoing need, with approximately 50,000 US deaths in 2023 NEWTOWN, Pa., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developi GlobeNewswire ? last month TRAW -0.98% Orbimed Advisors LLC Reduces Stake in Traws Pharma Inc On September 16, 2024, Orbimed Advisors LLC executed a significant transaction involving the shares of Traws Pharma Inc (NASDAQ:TRAW), a company operating within the biopharmaceutical sector. The firm decided to reduce its holdings by 24,080 shares, with the transaction occurring at a price of $8.50 per share. This move marks a notable adjustment in Orbimed Advisors LLC's investment strategy concerning Traws Pharma Inc. GuruFocus.com ? last month TRAW -0.98% Upcoming Stock Splits This Week (September 23 to September 27) – Stay Invested These are the upcoming stock splits for the week of September 23 to September 27, based on TipRanks’ Stock Splits Calendar. A stock split is a corporate action in which the company issues additional common shares to increase the number of outstanding shares. Accordingly, the stock price of the company’s shares decreases, which maintains the market capitalization before and after the split. In contrast, there are also reverse stock splits that reduce the number of outstanding shares (consolidate) TipRanks ? last month OTRK OTRKP TRAW -0.98% Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors Experienced Life Sciences Executive Brings Strategic Expertise to Support Traws’ Further Transformation and Growth Director James J Marino Also to Step Down from Traws Board After a Decade of Service NEWTOWN, Pa., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW) (“Traws” or “the Company”), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases and cancer, today announced the appointment of Luba Green GlobeNewswire ? last month TRAW -0.98% Traws Pharma, Inc. Announces Special Shareholders Meeting Results Three proposals, including a reverse stock split, were submitted and approved Traws Board subsequently approved a 1-for-25 reverse stock split Traws’ shares expected to begin trading on a split-adjusted basis on September 23, 2024 NEWTOWN, Pa., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW) (“Traws” or “the Company”), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases and cancer, today announce GlobeNewswire ? last month TRAW -0.98% Traws Pharma Reports Q2 2024 Financial Results,?Provides Recent Business Highlights Merger with Trawsfynydd Therapeutics, Inc (“Trawsfynydd”) and concurrent private placement of $14 million (cash runway to support planned operations through year end), with recently achieved clinical milestones, put Traws on track to achieve key readouts for the clinical pipeline in H2 2024 and beyond Lead antiviral program, tivoxavir marboxil, for influenza, including avian flu, is dosing the first cohort in the Phase 1 dose extension study in AustraliaCOVID-19 program, ratutrelvir, completed t GlobeNewswire ? 2 months ago TRAW -0.98% Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET NEWTOWN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and cancer, today announced that following the release of its second quarter financial results, the Company intends to host a conference call and live webcast on Thursday, August 15, at 8:00 AM ET to provide a corporate update. Conference Call and Webcast InformationDate: Thursday, August 15, 2024 GlobeNewswire ? 2 months ago TRAW -0.98% Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate Differentiated resistance profile positions Traws’ program as a potential class leaderNEWTOWN, Pa., May 23, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and cancer, today announced presentation of a poster at the annual International Conference on Antiviral Research (ICAR2024) which is being held from May 20th to May 24th in Gold Coast, Australia. The poster highl GlobeNewswire ? 5 months ago TRAW -0.98% Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update Completed acquisition of Trawsfynydd and concurrent $14 million Capital Raise Excellent pipeline progress, led by candidates for COVID 19, influenza, and oncology programs Poised to initiate Phase 2 studies in H2 2024 for our influenza candidate and ritonavir-free COVID 19 protease inhibitor NEWTOWN, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and ca GlobeNewswire ? 5 months ago TRAW -0.98% Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy Investigational travatrelvir demonstrated preclinical activity against multiple SARS-CoV-2 variants Orally administered novel protease inhibitor does not require ritonavir co-administration First-in-Human study to evaluate safety, tolerability and pharmacokinetics in healthy volunteers Topline Phase 1 data and Phase 2 initiation expected in H2 2024 NEWTOWN, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing GlobeNewswire ? 5 months ago TRAW -0.98% Traws Pharma Full Year 2023 Earnings: Beats Expectations Traws Pharma ( NASDAQ:TRAW ) Full Year 2023 Results Key Financial Results Net loss: US$18.9m (flat on FY 2022). US$0.90... Simply Wall St. ? 6 months ago ONTX TRAW -0.98% Performance Overview Trailing total returns as of 11/1/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return TRAW S&P 500 YTD -73.07% +20.28% 1-Year -68.44% +36.80% 3-Year -94.16% +24.58%
